105 related articles for article (PubMed ID: 16960766)
21. Costs associated with ventricular assist device use in children.
Mahle WT; Ianucci G; Vincent RN; Kanter KR
Ann Thorac Surg; 2008 Nov; 86(5):1592-7. PubMed ID: 19049755
[TBL] [Abstract][Full Text] [Related]
22. Costing and perspective in published cost-effectiveness analysis.
Neumann PJ
Med Care; 2009 Jul; 47(7 Suppl 1):S28-32. PubMed ID: 19536023
[TBL] [Abstract][Full Text] [Related]
23. The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review.
Harrison MJ; Davies LM; Bansback NJ; Ingram M; Anis AH; Symmons DP
J Rheumatol; 2008 Apr; 35(4):592-602. PubMed ID: 18278841
[TBL] [Abstract][Full Text] [Related]
24. [Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration].
Neubauer AS; Holz FG; Schrader W; Back EI; Kühn T; Hirneiss C; Kampik A
Klin Monbl Augenheilkd; 2007 Sep; 224(9):727-32. PubMed ID: 17846963
[TBL] [Abstract][Full Text] [Related]
25. A value-based medicine cost-utility analysis of idiopathic epiretinal membrane surgery.
Gupta OP; Brown GC; Brown MM
Am J Ophthalmol; 2008 May; 145(5):923-8. PubMed ID: 18329000
[TBL] [Abstract][Full Text] [Related]
26. Costs and quality of life of multiple sclerosis in Germany.
Kobelt G; Berg J; Lindgren P; Elias WG; Flachenecker P; Freidel M; König N; Limmroth V; Straube E
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S34-44. PubMed ID: 17310337
[TBL] [Abstract][Full Text] [Related]
27. Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol.
Ariza-Ariza R; Hernández-Cruz B; Carmona L; Dolores Ruiz-Montesinos M; Ballina J; Navarro-Sarabia F;
Arthritis Rheum; 2006 Oct; 55(5):751-6. PubMed ID: 17013822
[TBL] [Abstract][Full Text] [Related]
28. Costs and quality of life of multiple sclerosis in Switzerland.
Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
[TBL] [Abstract][Full Text] [Related]
29. Depression-free day to utility-weighted score: is it valid?
Pyne JM; Tripathi S; Williams DK; Fortney J
Med Care; 2007 Apr; 45(4):357-62. PubMed ID: 17496720
[TBL] [Abstract][Full Text] [Related]
30. Methods for determining cost-benefit ratios for pharmaceuticals in Germany.
von der Schulenburg J; Vauth C; Mittendorf T; Greiner W
Eur J Health Econ; 2007 Sep; 8 Suppl 1():S5-31. PubMed ID: 17582539
[TBL] [Abstract][Full Text] [Related]
31. Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer.
van den Hout WB; Kramer GW; Noordijk EM; Leer JW
J Natl Cancer Inst; 2006 Dec; 98(24):1786-94. PubMed ID: 17179480
[TBL] [Abstract][Full Text] [Related]
32. A note on the nature of utility in time and health and implications for cost utility analysis.
Buckingham KJ; Devlin NJ
Soc Sci Med; 2009 Jan; 68(2):362-7. PubMed ID: 19019518
[TBL] [Abstract][Full Text] [Related]
33. Advantages and limitations of utility assessment methods in rheumatoid arthritis.
Beresniak A; Russell AS; Haraoui B; Bessette L; Bombardier C; Duru G
J Rheumatol; 2007 Nov; 34(11):2193-200. PubMed ID: 17937471
[TBL] [Abstract][Full Text] [Related]
34. Costs and quality of life in multiple sclerosis in The Netherlands.
Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJ; Polman C; Uitdehaag B
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S55-64. PubMed ID: 17310343
[TBL] [Abstract][Full Text] [Related]
35. A new and more robust test of QALYs.
Doctor JN; Bleichrodt H; Miyamoto J; Temkin NR; Dikmen S
J Health Econ; 2004 Mar; 23(2):353-67. PubMed ID: 15019761
[TBL] [Abstract][Full Text] [Related]
36. HEE-GER: a systematic review of German economic evaluations of health care published 1990-2004.
Schwappach DL; Boluarte TA
BMC Health Serv Res; 2007 Jan; 7():7. PubMed ID: 17222334
[TBL] [Abstract][Full Text] [Related]
37. Quality-adjusted life years: how useful in medico economic studies.
Brauer CA; Neumann PJ
Fundam Clin Pharmacol; 2005 Dec; 19(6):603-7. PubMed ID: 16313271
[TBL] [Abstract][Full Text] [Related]
38. Patient preferences and cost-utility analysis.
Elnitsky CA; Stone P
Appl Nurs Res; 2005 May; 18(2):74-6. PubMed ID: 15991103
[TBL] [Abstract][Full Text] [Related]
39. A semi-separable utility function for health profiles.
Guerrero AM; Herrero C
J Health Econ; 2005 Jan; 24(1):33-54. PubMed ID: 15617787
[TBL] [Abstract][Full Text] [Related]
40. The subjective costs of health losses due to chronic diseases. An alternative model for monetary appraisal.
Ferrer-i-Carbonell A; van Praag BM
Health Econ; 2002 Dec; 11(8):709-22. PubMed ID: 12457371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
